Abstract:
The present invention relates to a process for the reduction of a 6-keto group in a morphinan alkaloid to the corresponding 6-hydroxy group, comprising hydrogenating the 6-keto group using gaseous hydrogen in the presence of a heterogeneous catalyst and a solvent, to yield the 6-hydroxy morphinan alkaloid, wherein the reduction is carried out at a pH in the range of about 5 to about 7, and the 6-hydroxy morphinan alkaloid has an α:β ratio of > 85:15.
PROCESS FOR REDUCING THE 6-KETO GROUP OF A MORPHINAN ALKALOID TO THE 6-HYDROXY GROUP BY HYDROGENATION

The present invention concerns an improved process for the synthesis of opiates, and more especially it concerns the reduction of a keto group in the 6-position of a morphinan alkaloid.

Naltrexol has been proposed as a treatment for heroin dependency. 6-β-Naltrexol is the major metabolite of naltrexone. We are interested in finding industrially applicable routes to 6α-naltrexol. Molecules of similar structure include α-noroxymorphone and α-nalbuphine.

The state of the art process for the production of such compounds involves the reduction of a 6-keto group on the corresponding naltrexone, noroxymorphone or 6-keto-nalbuphine using a borohydride, especially at low temperatures. This process is described in US 5,756,745 (Mallinckrodt). Such borohydride reductions have been found to be difficult to scale up to commercial scale production, there are safety issues associated with storing and using borohydrides and the by-product boron salts need to be removed from the product.

WO2006/035195 (Johnson Matthey) describes the conversion of noroxymorphone to nalbuphine by a hydrogenation using platinum on carbon catalyst, followed by sodium borohydride addition.

WO2008/137672 (Mallinckrodt) aims to avoid the use of borohydride by the use of a ruthenium, rhodium or iridium asymmetric catalyst in combination with a hydrogen source and a solvent. The typical chiral catalysts are Noyori catalysts. Hydrogen sources include gaseous hydrogen at up to 100 atm or, preferably, a hydrogen transfer agent such as isopropanol or formic acid. If isopropanol is used, a small amount of activator such as KOH may be added, but the preferred hydrogen source is a 5:2 mixture of formic acid and triethylamine. Yields are stated to be 83% for nalbuphine, with a 99:1 6α-nalbuphine to 6β-nalbuphine ratio.

There remains a need for simple and inexpensive reduction method for this transformation.

This invention therefore provides a process for the reduction of a 6-keto group in a morphinan alkaloid to the corresponding 6-hydroxy group, comprising hydrogenating the 6-keto group using gaseous hydrogen in the presence of a heterogeneous catalyst and a solvent, to yield the 6-hydroxy product.

The molecules to which this reduction can be applied are noroxymorphone, naltrexone, 6-keto-nalbuphine, hydromorphone, hydrocodone, oxycodone, oxymorphone and naloxone.

In brief, the process of the invention may be represented by the reaction scheme in Figure 1.
The inventors have found that, although the heterogeneous catalyst is not asymmetric, the reduction may be stereoselective. In a preferred embodiment, the 6α-hydroxy stereoisomer is the major product. More preferably, the 6α-hydroxy group is produced in an α:β ratio of >85:15. For example, the 6α-hydroxy group is produced in an α:β ratio of 86:14. Even more preferably, the 6α-hydroxy group is produced in an α:β ratio of ≥ 90:10. For example, under desired conditions the 6α-hydroxy group is produced in an α:β ratio of ≥ 93:7. Even more preferably, the 6α-hydroxy group is produced in an α:β ratio of ≥ 94:6. For example, the 6α-hydroxy group is produced in an α:β ratio of ≥ 95:5. In one particularly preferred embodiment, an α:β ratio of 98:2 can be obtained. Resolution of the stereoisomers may readily be carried out using conventional HPLC methods.

The reduction is carried out in the presence of a heterogeneous catalyst. Preferably, the heterogeneous catalyst is a platinum group metal on a solid support. More preferably, the heterogeneous catalyst is selected from the group consisting of palladium on carbon, rhodium on carbon, platinum on carbon, iridium on carbon, ruthenium on carbon and mixtures thereof.

The catalyst loading may be up to about 10 mole%. In one embodiment, the catalyst loading may be up to 5 mole% concentration and, in one preferred embodiment, about 0.4-1.0 mole %. Sources of catalyst and sources of solid support do vary, and it is recommended that the catalyst is selected by conventional trial and error optimisation.

The hydrogen pressure is suitably in the range of up to about 100 psi and is suitably approximately 40 psi (about 2.758 bar).

If the alkaloid has one or more substituents which may be adversely affected during the reduction, such as 3-hydroxy or 14-hydroxy groups, these may be protected in a conventional manner. Alternatively, if these substituents have been protected prior to the hydrogenation reaction (for example, in steps leading to the synthesis of the 6-keto morphinan alkaloid), the protecting group(s) may be selected such that simultaneous hydrogenation of the 6-keto group and deprotection occurs. Suitable protecting groups which are capable of withstanding hydrogenation or are removed during hydrogenation are known in the art (see, for example, "Protective Groups in Organic Chemistry", Peter G. M. Wuts and Theodora W. Greene, Wiley Blackwell).

The inventors have identified that it is possible to carry out the hydrogenation at acidic, neutral or alkaline pHs. Preferably therefore the reduction may be carried out at a pH in the range of about 0 to about 13. A particularly preferred range is from about pH 5 to about 7. In this instance, the inventors have identified that it is possible to minimise the formation of the β
stereoisomer and further improve the present process by minimising degradation and loss of yield.

In one embodiment, the process further comprises an acid. Preferably, the acid is an organic acid such as acetic acid, or an inorganic acid such as phosphoric acid, orthophosphoric acid or hydrochloric acid.

Any suitable solvent may be utilised e.g. aqueous solvents, polar solvents, aprotic dipolar solvents, non-polar solvents or mixtures thereof. In one embodiment, the solvent is suitably water, and desirably a co-solvent is used. The co-solvent may be a polar solvent, such as an alcohol. In this instance, the alcohol may be selected from the group consisting of methanol, ethanol, isopropanol and mixtures thereof. A preferred alcohol is isopropanol (IPA). Desirably, the quantity of isopropanol is kept at or below about 50 vol%, since conversion and the α:β ratio appear to be adversely affected with increasing isopropanol quantities above about 50 vol%. Alternatively, the co-solvent may be a non-polar solvent, such as an aromatic hydrocarbon e.g. toluene. In an embodiment, the solvent may be a mixture of polar solvents, such as a cyclic amide (e.g. N-methyl pyrrolidone) and an alcohol (e.g. methanol, ethanol or isopropanol, preferably methanol).

Reaction temperatures are suitably in the range from 20 to 75°C, preferably in the range from about 25 to about 60°C, most preferably about 35 to about 50°C.

The 6-keto group may be in a tautomeric equilibrium with its corresponding enol and a number of factors may influence this equilibrium. These factors include the pH or temperature at which the reduction is conducted, the solvent used or concentration of the morphinan alkaloid reactant. If the enol tautomer is present, however, its hydrogenation will still yield the desired 6-hydroxy morphinan alkaloid. As such, the present invention encompasses the reduction of the 6-keto group, the corresponding enol of the 6-keto group or a tautomeric mixture thereof.

It has been observed that the reduction of the 6-keto group in the morphinan alkaloid may be completed within about 24 hours and more preferably, within about 1 hour to about 8 hours.

The product may be isolated and purified using conventional techniques. For example, once the reduction is complete, work up may involve pH adjustment to ensure that the alkaloid components are in solution, followed by the removal of the catalyst by filtration, then basification of the filtrate to precipitate the alkaloid components, cooled (if necessary) and subsequently filtered and washed. Typical purification methods may involve one or more recrystallisations.
Acid addition salts of the 6-hydroxy morphinan alkaloid may be prepared if desired. In this instance, any suitable salt may be prepared, preferably a pharmaceutically acceptable salt. Hydrochloride salts are particularly preferred. Methods for preparing salts are well known to the skilled person. In an exemplary process, the 6-hydroxy morphinan alkaloid may be converted to its acid addition salt by heating a slurry of the 6-hydroxy morphinan alkaloid with an alcohol (e.g. ethanol) or alcohol/water mixture, adding the acid, followed by cooling and filtration. The salt may then be optionally recrystallised if desired.

The process of the present invention may additionally comprise a reductive alkylation reaction before, after or simultaneously with the reduction of the 6-keto group. WO2006/035195 (Johnson Matthey) relates to the reductive alkylation of morphinan alkaloids, the contents of which are incorporated herein by reference. In this instance, noroxymorphone and noroxymorphinol are useful substrates as they may be alkylated to form a series of 14-hydroxylated opiate derivatives.

The invention will now be described by way of the following non-limiting Examples.

**Example 1**
Reduction of 6-ketonalbuphine to generate Nalbuphine alkaloid

6-ketonalbuphine (40g, 112.8 mmoles) was dissolved in a mixture of IPA (200 ml) and water (200 ml) containing orthophosphoric acid (1.56 ml). The pH of the reaction mixture was 6.49. The reaction mixture was hydrogenated at 40 psi hydrogen gas and 50°C in the presence of 10% Platinum on carbon catalyst (2.4g, 0.56 mmoles Pt). After 7 hours, the pH of the reaction mixture is adjusted with orthophosphoric acid (6.25 ml) and filtered. Ammonia solution (25 ml) was added to bring the pH to 8.5 - 9.0 and the precipitate filtered, washed with 50% aqueous IPA (60 ml), and dried to provide 39.33 g (97% theory) of Nalbuphine alkaloid of purity 95.6% by HPLC.

**Conversion of Nalbuphine alkaloid to Nalbuphine hydrochloride**
Nalbuphine alkaloid (33.1g) was charged to a flask containing ethanol (79ml) and water (20 ml) and the mixture heated to 50°C. Concentrated Hydrochloric acid (9.1 ml) was added to adjust to within the pH range 4 - 4.5. The resulting solution was cooled to <10°C using an ice bath and held for ~2 hours and filtered. The Nalbuphine hydrochloride solid was washed with ethanol:water (10.6ml:2.6ml) and dried at 55°C in a fan oven to afford 35.27 g (89% theory) of Nalbuphine hydrochloride.

**Example 2**
Reduction of hydromorphone to generate dihydromorphone
Hydromorphone (10g) was charged to a Parr hydrogenator flask followed by IPA (50ml), water (50ml), and orthophosphoric acid (0.37ml). 10% Pt/C catalyst (1.49g) were added and the
mixture hydrogenated at 50°C and 40 psi hydrogen for 1 hour when HPLC (against a reference standard) showed the mixture to comprise solely dihydromorphine.

Example 3

Reduction of noroxymorphone to generate Noroxymorphinol

Noroxymorphone alkaloid (2 g) was charged to a flask containing water (5 ml), and hydrochloric acid (0.43 mis). Rh / C catalyst (1 mole %) was added and the reaction hydrogenated at 40 psi hydrogen and 35°C for 7 hours. HPLC analysis indicated a 98 % conversion to Noroxymorphinol with an α:β ratio of diastereomers of 95:5.

Example 4

Reduction of naltrexone to generate Naltrexol

Naltrexone (20.0g), IPA (100ml), water (100ml) and H₃PO₄ (0.6ml) were charged to a 250ml reaction flask and heated to 50°C. 10% Pt/C catalyst (1.3g) was added and the reaction hydrogenated at 50°C and 40 psi for a period of 7hrs. Harborlite (0.2g) was added and the batch filtered to remove catalyst residues. Ammonia solution (2 mis) was added to adjust the pH to 8.0 - 9.0 whereupon the mixture was cooled to <10°C, filtered, washed with water (20 mis), and dried at 55°C. 11.16 g (55.5 % yield) of a beige solid, corresponding to α-Naltrexol by HPLC was obtained. ¹H NMR (CDCl₃ δ/ppm) 0.00 (4H, m), 0.39 (4H,m), 0.70 (2H,m), 1.00 (2H,m), 1.30 (2H, m), 1.51 (6H,m), 2.10 (4H, m), 2.20 (4H, m), 2.45 (4H,m), 3.41 (1H, m), 4.15 (1H,m), 4.41 (1H, d, J = 6 Hz), 4.55 (1H, d, J = 6 Hz), 6.35 (1H, d, J = 10 Hz), 6.55 (1H, d, J = 10 Hz), 5.10 - 5.70 (6H, very broad s). ¹³C NMR (CDCl₃ δ/ppm) 3.86, 4.09, 9.45, 22.89, 23.20, 28.91, 33.46, 43.28, 47.50, 59.65, 62.16, 67.02, 70.13, 90.74, 117.92, 119.2, 125.5, 131.1, 137.7, 145.9

Example 5

Reduction of hydrocodone to generate dihydrocodeine

Hydrocodone (10g) was charged to a Parr hydrogenator flask followed by water (50ml), IPA (50ml) and phosphoric acid (0.3ml). 10% Pt/C catalyst (1.42g) was added and the mixture hydrogenated at 50°C and 40 psi hydrogen. Hydrogen uptake was observed to cease after 5 hours and harborlite added to the crude reaction mixture which was then filtered. HPLC analysis indicated that the major product formed correlated with a dihydrocodeine reference standard.

Example 6

Reduction of Oxycodone to generate oxycodol

Oxycodone (5g) was charged to a Parr hydrogenator flask followed by water (50ml), and hydrochloric acid (0.3ml). 10% Rh/C catalyst (1.51g) was added and the mixture hydrogenated at 35°C and 40 psi hydrogen. Hydrogen uptake was observed to cease after 6
hours and harborlite added to the crude reaction mixture which was then filtered. HPLC analysis indicated that the major product formed correlated with a oxycodol reference standard.

Example 7
Telescope of the Reductive alkylation & Asymmetric ketone reduction reactions (Naltrexol)
Noroxymorphone (10g, 34.8 mmoles) were charged to a hydrogenator flask along with NMP (30 mis) and Methanol (70 mis), and cyclopropane carboxaldehyde (2.5 mis, 38.5 mmoles). 5 % Pt / C (0.32g) was added and the mixture hydrogenated under 40 psi hydrogen gas for 3 hours. Harborlite (0.2g) was added and the mixture filtered. Water (100 mis) was added to the filtered reaction solution and the resulting slurry was cooled to 0 - 5°C. The precipitate was removed by filtration and stored until recombined with toluene extracts (150mls) obtained from extracting active material from the filtrate with toluene (5><30mis). The combined toluene extracts were then washed with water (5><30mis) and recombined with the previously filtered solid precipitate. A solution of aqueous acetic acid (80 mis, 1.6 %) was then added to the reaction slurry in toluene and heated to 5°C. Once all the solid was dissolved (10 minutes), the two layers were separated and the aqueous later cooled to 20 - 3°C. 5 % Pt / C catalyst (2.83 g) was added and the mixture hydrogenated at 5°C and 40 psi for 2 hours. HPLC analysis showed the major product formed to be α-Naltrexol.

Example 8
One Pot Reductive alkylation & Asymmetric ketone reduction reactions (Naltrexol)
Noroxymorphone (10g, 34.8 mmoles) were charged to a hydrogenator flask along with NMP (30 mis) and Methanol (70 mis), and cyclopropane carboxaldehyde (2.5 mis, 38.5 mmoles). 5 % Pt / C (0.32g) was added and the mixture hydrogenated under 40 psi hydrogen gas for 3 hours. Harborlite (0.2g) was added and the mixture filtered. A fresh charge of 5 % Pt / C (2.7 g) was added to the mixture which was then hydrogenated at 5°C and 40 psi hydrogen for 2 hours. HPLC analysis showed the reaction solution to contain α-Naltrexol.

Example 9
One Pot Reductive alkylation & Asymmetric ketone reduction reactions (Nalbuphine)
Noroxymorphone (2g, 6.9 mmoles) were charged to a hydrogenator flask along with NMP (6 mis) and Methanol (14 mis), and cyclobutane carboxaldehyde (0.67 mis). 5 % Pt / C (3.15 g) was added and the mixture hydrogenated under 40 psi hydrogen at 5°C for 3 hours. At the end of the reaction, HPLC analysis against a reference sample showed α-Nalbuphine to be the major product formed.

Example 10
α:β Ratio of 6-Hydroxy Morphinan Alkaloids
The table below details the α:β ratio of 6-hydroxy morphinan alkaloids produced according to the process of the present invention.

<table>
<thead>
<tr>
<th>6-Keto Morphinan Alkaloid</th>
<th>6-Hydroxy Morphinan Alkaloid</th>
<th>Catalyst</th>
<th>α:β Ratio of 6-Hydroxy Morphinan Alkaloid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxycodone</td>
<td>Oxycodol</td>
<td>Rh/C</td>
<td>93:7</td>
</tr>
<tr>
<td>6-Keto-nalbuphine</td>
<td>Nalbuphine</td>
<td>Pt/C</td>
<td>95:5</td>
</tr>
<tr>
<td>Naltrexone</td>
<td>Naltrexol</td>
<td>Rh/C</td>
<td>94:6</td>
</tr>
<tr>
<td>Naltrexone</td>
<td>Naltrexol</td>
<td>Pt/C</td>
<td>93:7</td>
</tr>
<tr>
<td>Noroxymorphone</td>
<td>Noroxymorphanol</td>
<td>Rh/C</td>
<td>95:5</td>
</tr>
<tr>
<td>Noroxymorphone</td>
<td>Noroxymorphanol</td>
<td>Pt/C</td>
<td>86:15</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>Dihydrocodeine</td>
<td>Pt/C</td>
<td>98:2</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>Dihydromorphine</td>
<td>Pt/C</td>
<td>98:2</td>
</tr>
</tbody>
</table>

The HPLC method used to determine the α:β ratio is as follows and is based on the European Pharmacopoeia method for naloxone hydrochloride:

- **Column**: Zorbax Eclipse XDB-C8 5 microns 12.5cm x 4.0mm
- **Mobile Phase**: Prepare a solution as follows: dissolve 1.17 g sodium octansulphonate in 1000ml water, adjust to pH 2.0 with a 50% v/v solution of phosphoric acid
  - A 20 ml acetonitrile, 40 ml THF and 940ml of above solution
  - B 170 ml acetonitrile, 40 ml THF and 790 ml of above solution
- **Flow rate**: 1.5 ml/ minute
- **Temperature**: 40°C
- **Detector**: UV @ 230nm
- **Injection volume**: 20 microlitres
- **Run time**: 45 minutes

**Linear gradient**:

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>A % v/v</th>
<th>B % v/v</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>40</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>50</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>55</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>65</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>
Claims

1. A process for the reduction of a 6-keto group in a morphinan alkaloid to the corresponding 6-hydroxy group, comprising hydrogenating the 6-keto group using gaseous hydrogen in the presence of a heterogeneous catalyst and a solvent, to yield the 6-hydroxy morphinan alkaloid, wherein the reduction is carried out at a pH in the range of about 5 to about 7, and the 6-hydroxy morphinan alkaloid has an α:β ratio of > 85:15.

2. A process according to claim 1, wherein the 6-keto morphinan alkaloid is selected from the group consisting of noroxymorphone, naltrexone, 6-keto-nalbuphine, hydromorphone, hydrocodone, oxycodone, oxymorphone and naloxone.

3. A process according to claim 1 or claim 2, wherein the heterogeneous catalyst is a platinum group metal on a solid support.

4. A process according to claim 3, wherein the heterogeneous catalyst is selected from the group consisting of palladium on carbon, rhodium on carbon, platinum on carbon, iridium on carbon, ruthenium on carbon and mixtures thereof.

5. A process according to any one of the preceding claims, further comprising an acid.

6. A process according to claim 5, wherein the acid is selected from the group consisting of phosphoric acid, orthophosphoric acid, acetic acid, hydrochloric acid and mixtures thereof.

7. A process according to any one of the preceding claims, wherein the solvent is selected from the group consisting of an aqueous solvent, a polar solvent, an aprotic dipolar solvent, a non-polar solvent and mixtures thereof.

8. A process according to claim 7, wherein the solvent is water.

9. A process according to claim 8, further comprising a co-solvent selected from the group consisting of a polar solvent, a non-polar solvent and mixtures thereof.

10. A process according to claim 7 or claim 9, wherein the polar solvent is an alcohol and/or cyclic amide.

11. A process according to claim 7 or claim 9, wherein the non-polar solvent is an aromatic hydrocarbon.
12. A process according to any one of the preceding claims, wherein the process is carried out at a temperature in the range from about 20 to about 75°C.

13. A process according to any one of the preceding claims, further comprising the resolution of the 6α and 6β stereoisomers by HPLC.

14. A process according to any one of the preceding claims, further comprising a reductive alkylation reaction before, after or simultaneously with the reduction of the 6-keto group.

15. A 6-hydroxy morphinan alkaloid obtainable according to the process as defined in any one of claims 1 to 14.
$R_1 = CH_3; \ R_2 = H$ : Hydromorphone
$R = R_1 = CH_3; \ R_2 = H$ : Hydrocodone
$R = R_1 = CH_3; \ R_2 = OH$ : Oxycodone
$R_1 = H; \ R_2 = OH; \ R = CH_3$ : Oxymorphone
$R = R_1 = H; \ R_2 = OH$ : Noroxymorphone
$R_1 = H; \ R_2 = OH; \ R = \text{Naloxone}$
$R_1 = H; \ R_2 = OH; \ R = \text{Naltrexone}$
$R_1 = H; \ R_2 = OH; \ R = \text{6-keto-Nalbuphine}$

$R_1 = CH_3; \ R = R_2 = H$ : Dihydromorphone
$R = R_1 = CH_3; \ R_2 = H$ : Dihydrocodeine
$R = R_1 = CH_3; \ R_2 = OH$ : Oxycodol
$R_1 = H; \ R_2 = OH; \ R = CH_3$ : Oxymorphonol
$R = R_1 = H; \ R_2 = OH$ : Noroxymorphonol
$R_1 = H; \ R_2 = OH; \ R = \text{Naloxol}$
$R_1 = H; \ R_2 = OH; \ R = \text{Naltrexol}$
$R_1 = H; \ R_2 = OH; \ R = \text{Nalbuphine}$
**INTERNATIONAL SEARCH REPORT**

---

**A. CLASSIFICATION OF SUBJECT MATTER**

INV. C07D489/02  C07D489/08

---

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

C07D

---

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 2006/035195 A1 (JOHNSON MATTHEY PLC [GB]; GOODWIN NEIL JOHN [GB]; MITCHELL MELVILLE) 6 April 2006 (2006-04-06) cited in the application page 6, lines 16-24; claims 1,7; example 4</td>
<td>1-15</td>
</tr>
<tr>
<td>X</td>
<td>LYNDON SMALL ET AL: &quot;The addition of organomagnesium halides to pseudocodeine types. II. Preparation of nuclear alkylated morphine derivatives&quot; JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 58, 1936, pages 1457-1463, XP002269519 ISSN: 0002-7863 page 1458, left column, 3 last lines; page 1462, left column, Methyl dihydromorphine; compounds VI; VII</td>
<td>1-15</td>
</tr>
</tbody>
</table>

---

**X** Further documents are listed in the continuation of Box C **X** See patent family annex

* Special categories of cited documents

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another document, or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance, the claimed invention cannot be considered as novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance, the claimed invention cannot be considered as involving an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "A" document member of the same patent family

**Date of the actual completion of the international search**

29 October 2010

**Date of mailing of the international search report**

22/11/2010

Name and mailing address of the ISA/

European Patent Office, P B 5818 Patentlaan 2

NL - 2280 WV Rijswijk

Tel (+31-70) 340-2040

Fax (+31-70) 340-3016

**Authorized officer**

Ladenburger, Claude
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>STEPHEN P. FINDLAY AND LYNDON R. SMALL: &quot;The acid-catalyzed conversion of codeinone to 8-hydroxydihydrocodeinone&quot; JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 73, 1951, pages 4001-4004, XP002607493 page 4002, scheme, III-&gt;IV; page 4004, compound IV, (a) catalytic hydrogenation; compounds III, IV</td>
<td>1-15</td>
</tr>
<tr>
<td>X</td>
<td>KAKUJI GOTO AND TATSUO ARAI: &quot;(+)-Dihydrocodein und (+)-Dihydromorphin aus Sinomenin&quot; JUSTUS LIEBIGS ANNALEN DER CHEMIE, vol. 547, 1941, pages 194-200, XP002607494 page 196, (+)-Dihydro-codein II; compounds I, II</td>
<td>1-15</td>
</tr>
<tr>
<td>X</td>
<td>STEPHEN P. FINDLAY: &quot;The three-dimensional structures of the cocaïnes. II. Racemic allococaine and racemic allopseudococaine&quot; JOURNAL OF ORGANIC CHEMISTRY, vol. 24, 1959, pages 1540-1550, XP002607495 page 1547, right column, the catalytic hydrogenation of dihydrocodeinone; compounds XI-XV</td>
<td>1-15</td>
</tr>
<tr>
<td>X</td>
<td>ROBERT E. LUTZ AND LYNDON SMALL: &quot;Reduction studies in the morphine series. IX. Hydroxycodeinone&quot; JOURNAL OF ORGANIC CHEMISTRY, vol. 4, 1939, pages 220-233, XP001005472 ISSN: 0022-3263 page 229, last paragraph; compound VI</td>
<td>1-15</td>
</tr>
<tr>
<td>X</td>
<td>HIDEAKI FUJII ET AL: &quot;Synthesis of N-isobutynoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction&quot; BIOORGANIC &amp; MEDICINAL CHEMISTRY LETTERS, vol. 18, no. 18, 2008, pages 4978-4981, XP025407653 ISSN: 0960-894X [retrieved on 2008-08-12] scheme 1, 11-&gt;13; table 1; compounds 3,5-8</td>
<td>1-15</td>
</tr>
<tr>
<td>Category</td>
<td>Citation of document with indication, where appropriate, of the relevant passages</td>
<td>Relevant to claim No</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>X,P</td>
<td>WO 2010/017573 A1 (TASMANIAN ALKALOIDS PTY LTD [AU]; BAILEY TIMOTHY S [AU]; REZAIE ROBERT) 18 February 2010 (2010-02-18) page 11, lines 6-21; claims 1-21; examples 1-6, 9, 10</td>
<td>1-15</td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (continuation of second sheet) (April 2005)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>AU 2005288728 A1</td>
<td>06-04-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 101027307 A</td>
<td>29-08-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 1794165 T3</td>
<td>08-03-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2322486 T3</td>
<td>22-06-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 1794165 E</td>
<td>06-05-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2008045715 A1</td>
<td>21-02-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 200701784 A</td>
<td>28-05-2008</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2010200188 A1</td>
<td>04-02-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2010200191 A1</td>
<td>04-02-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2637610 A1</td>
<td>04-11-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2152715 A1</td>
<td>17-02-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2180000 A1</td>
<td>28-04-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2189460 A1</td>
<td>26-05-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2009534472 T</td>
<td>24-09-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010041888 A1</td>
<td>18-02-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010113788 A1</td>
<td>06-05-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010081818 A1</td>
<td>01-04-2010</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>WO 2010017573 A1</td>
<td>18-02-2010</td>
<td>US 2010036128 A1</td>
<td>11-02-2010</td>
</tr>
</tbody>
</table>